These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 32827153)

  • 1. Combining primary cohort data with external aggregate information without assuming comparability.
    Chen Z; Ning J; Shen Y; Qin J
    Biometrics; 2021 Sep; 77(3):1024-1036. PubMed ID: 32827153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accommodating time-varying heterogeneity in risk estimation under the Cox model: a transfer learning approach.
    Li Z; Shen Y; Ning J
    J Am Stat Assoc; 2023; 118(544):2276-2287. PubMed ID: 38505403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct epidemiological profiles associated with inflammatory breast cancer (IBC): A comprehensive analysis of the IBC registry at The University of Texas MD Anderson Cancer Center.
    Fouad TM; Ueno NT; Yu RK; Ensor JE; Alvarez RH; Krishnamurthy S; Lucci A; Reuben JM; Yang W; Willey JS; Valero V; Bondy ML; Cristofinalli M; Shete S; Woodward WA; El-Zein R
    PLoS One; 2018; 13(9):e0204372. PubMed ID: 30248155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficient Estimation of the Cox Model With Auxiliary Subgroup Survival Information.
    Huang CY; Qin J; Tsai HT
    J Am Stat Assoc; 2016; 111(514):787-799. PubMed ID: 27990035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Semiparametric estimation of the transformation model by leveraging external aggregate data in the presence of population heterogeneity.
    Cheng YJ; Liu YC; Tsai CY; Huang CY
    Biometrics; 2023 Sep; 79(3):1996-2009. PubMed ID: 36314375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.
    Masuda H; Brewer TM; Liu DD; Iwamoto T; Shen Y; Hsu L; Willey JS; Gonzalez-Angulo AM; Chavez-MacGregor M; Fouad TM; Woodward WA; Reuben JM; Valero V; Alvarez RH; Hortobagyi GN; Ueno NT
    Ann Oncol; 2014 Feb; 25(2):384-91. PubMed ID: 24351399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fitting additive risk models using auxiliary information.
    Ding J; Li J; Han Y; McKeague IW; Wang X
    Stat Med; 2023 Jan; ():. PubMed ID: 36599810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A unified approach for synthesizing population-level covariate effect information in semiparametric estimation with survival data.
    Huang CY; Qin J
    Stat Med; 2020 May; 39(10):1573-1590. PubMed ID: 32073677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous selection and incorporation of consistent external aggregate information.
    Huang Y; Huang CY; Kim MO
    Stat Med; 2023 Dec; 42(30):5630-5645. PubMed ID: 37788982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The project data sphere initiative: accelerating cancer research by sharing data.
    Green AK; Reeder-Hayes KE; Corty RW; Basch E; Milowsky MI; Dusetzina SB; Bennett AV; Wood WA
    Oncologist; 2015 May; 20(5):464-e20. PubMed ID: 25876994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating the incidence of inflammatory breast cancer using population- and hospital-based cancer registries in Casablanca, Morocco.
    Gunden JR; Bendahhou K; Benider A; Ibrahim Khalil A; Khalis M; Wilson ML; Soliman AS
    Breast Dis; 2019; 38(2):39-45. PubMed ID: 31104003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation Study of the American Joint Committee on Cancer Eighth Edition Prognostic Stage Compared With the Anatomic Stage in Breast Cancer.
    Weiss A; Chavez-MacGregor M; Lichtensztajn DY; Yi M; Tadros A; Hortobagyi GN; Giordano SH; Hunt KK; Mittendorf EA
    JAMA Oncol; 2018 Feb; 4(2):203-209. PubMed ID: 29222540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical effectiveness and cost-effectiveness of different surveillance mammography regimens after the treatment for primary breast cancer: systematic reviews registry database analyses and economic evaluation.
    Robertson C; Arcot Ragupathy SK; Boachie C; Dixon JM; Fraser C; Hernández R; Heys S; Jack W; Kerr GR; Lawrence G; MacLennan G; Maxwell A; McGregor J; Mowatt G; Pinder S; Ternent L; Thomas RE; Vale L; Wilson R; Zhu S; Gilbert FJ
    Health Technol Assess; 2011 Sep; 15(34):v-vi, 1-322. PubMed ID: 21951942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesizing external aggregated information in the penalized Cox regression under population heterogeneity.
    Sheng Y; Sun Y; Huang CY; Kim MO
    Stat Med; 2021 Oct; 40(23):4915-4930. PubMed ID: 34134178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identifying the impact of inflammatory breast cancer on survival: a retrospective multi-center cohort study.
    Diessner J; Van Ewijk R; Weiss CR; Janni W; Wischnewsky MB; Kreienberg R; Hancke K; Blettner M; Wöckel A; Schwentner L
    Arch Gynecol Obstet; 2015 Sep; 292(3):655-64. PubMed ID: 25814296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Italian cancer figures--Report 2015: The burden of rare cancers in Italy.
    ; Busco S; Buzzoni C; Mallone S; Trama A; Castaing M; Bella F; Amodio R; Bizzoco S; Cassetti T; Cirilli C; Cusimano R; De Angelis R; Fusco M; Gatta G; Gennaro V; Giacomin A; Giorgi Rossi P; Mangone L; Mannino S; Rossi S; Pierannunzio D; Tavilla A; Tognazzo S; Tumino R; Vicentini M; Vitale MF; Crocetti E; Dal Maso L
    Epidemiol Prev; 2016; 40(1 Suppl 2):1-120. PubMed ID: 26951748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Censored linear regression in the presence or absence of auxiliary survival information.
    Sheng Y; Sun Y; Deng D; Huang CY
    Biometrics; 2020 Sep; 76(3):734-745. PubMed ID: 31785156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statin use in primary inflammatory breast cancer: a cohort study.
    Brewer TM; Masuda H; Liu DD; Shen Y; Liu P; Iwamoto T; Kai K; Barnett CM; Woodward WA; Reuben JM; Yang P; Hortobagyi GN; Ueno NT
    Br J Cancer; 2013 Jul; 109(2):318-24. PubMed ID: 23820253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathologic complete response and overall survival in breast cancer subtypes in stage III inflammatory breast cancer.
    van Uden DJP; van Maaren MC; Bult P; Strobbe LJA; van der Hoeven JJM; Blanken-Peeters CFJM; Siesling S; de Wilt JHW
    Breast Cancer Res Treat; 2019 Jul; 176(1):217-226. PubMed ID: 30972613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidemiological risk factors associated with inflammatory breast cancer subtypes.
    Atkinson RL; El-Zein R; Valero V; Lucci A; Bevers TB; Fouad T; Liao W; Ueno NT; Woodward WA; Brewster AM
    Cancer Causes Control; 2016 Mar; 27(3):359-66. PubMed ID: 26797453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.